Wildeshausen

Researchers are evaluating various approved injectable and oral disease-modifying treatments (DMTs) in patients with relapsing multiple sclerosis (RMS) in Germany. This observational, non-interventional, multicenter, open-label study collects primary data prospectively over up to four years, alongside retrospective data. The study captures medical history, disease duration, laboratory values, disability scores (EDSS), MRI results, and relapse information to provide real-world insights into treatment use and outcomes. Patients receiving routine medical treatment with any approved injectable or selected oral DMTs—including ofatumumab, glatiramer acetate, interferon 21, teriflunomide, dimethyl fumarate, and diroximel fumarate—are enrolled without treatment allocation by the study. Two cohorts are observed: one treated primarily with injectable DMTs and another with injectable or oral DMTs. The core study period lasts about two years, with an optional extension providing an additional two years of observation, totaling up to four years. Follow-up visits and monitoring happen at the investigator's discretion and may include telemedicine. During the study, participants provide data through questionnaires and electronic case report forms. Routine clinical care procedures, such as diagnostic tests and monitoring, continue as usual. Researchers measure the proportion of patients continuing their baseline treatment at 24 months and collect ongoing clinical and imaging data. The study emphasizes real-world treatment patterns, safety, and disease activity over the extended follow-up period.

Long bone defect (LBD) is a focal loss of bone tissue in any long bone of the arms or legs, often caused by trauma, tumors, or infection, with post-traumatic defects being the most common. Limb reconstruction for these defects is complex and currently lacks strong evidence-based treatment guidelines. This international, multicenter registry aims to collect detailed information about the prevalence, treatments, complications, and outcomes of long bone defects over a three-year period. The registry includes any treatment used for long bone defects, with treatment decisions made by individual clinicians based on patient characteristics. No specific treatment is dictated by the registry. The study plans to enroll at least 600 patients from participating sites worldwide. Surgical interventions and other therapies applied to treat bone defects will be documented along with patient-related and other defined outcome measures. Participants will undergo assessments at multiple time points including pre-operative, intraoperative, and follow-up visits up to 12 to 18 months after bone union. These assessments cover baseline characteristics, bone defect details, trauma evaluation, surgical findings, functional outcomes, quality of life, and radiological results. Data collected will help understand treatment strategies, identify challenges, and improve clinical evidence for managing long bone defects.